ReviewFrontiers in immunology2025
Latent autoimmune diabetes in youth.
Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An unusual combination of latent autoimmune diabetes in young and maturity-onset diabetes in young.JCEM case reports · 2026Article
- Proteomic Changes in Patients with LADA-Type Diabetes: Prospects for Diagnostic Biomarkers.International journal of molecular sciences · 2026Review
- Case Report: Latent autoimmune diabetes in two young female patients successfully treated with oral semaglutide and basal insulin.Frontiers in endocrinology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Latent autoimmune diabetes in youth (LADY) is an emerging and under-recognized subtype of autoimmune diabetes, occurring in young individuals who present with clinical features overlapping both type 1 and type 2 diabetes. LADY shares pathophysiological characteristics with latent autoimmune diabetes in adults (LADA) yet differs in its earlier onset and stronger autoimmune response. Due to its heterogeneous presentation, LADY is frequently misclassified as type 2 diabetes in youth, leading to delays in appropriate treatment. Moreover, there are currently no universally accepted diagnostic criteria or screening strategies specific to LADY. As a result, clinical management remains inconsistent and controversial. Given the rising incidence of autoimmune diabetes in youth and the clinical consequences of delayed diagnosis, there is an urgent need to better characterize LADY and develop age-specific diagnostic and therapeutic approaches. In this review, we summarize the current knowledge regarding the epidemiology, pathogenesis, clinical features, diagnostic challenges, and treatment strategies of LADY. We also highlight the existing knowledge gaps and propose directions for future research and clinical practice with the aim of improving the recognition and management of this unique diabetes subtype in the pediatric population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.